Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Conditions
Keywords
stage III bladder cancer, recurrent bladder cancer, stage IV bladder cancer, transitional cell carcinoma of the bladder, recurrent urethral cancer, distal urethral cancer, proximal urethral cancer, urethral cancer associated with invasive bladder cancer, metastatic transitional cell cancer of the renal pelvis and ureter, regional transitional cell cancer of the renal pelvis and ureter, recurrent transitional cell cancer of the renal pelvis and ureter
Brief summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have advanced cancer of the urothelium with decreased kidney function.
Detailed description
OBJECTIVES: * Determine the response rate of patients with progressive regional or metastatic transitional cell carcinoma of the urothelium with renal insufficiency when treated with paclitaxel and gemcitabine. * Determine the toxicity of this regimen in this patient population. OUTLINE: Patients receive paclitaxel IV over 1 hour followed immediately by gemcitabine IV over 30 minutes on days 1, 8, and 15. Treatment continues every 4 weeks for a minimum of 3 courses in the absence of unacceptable toxicity or disease progression. Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter. PROJECTED ACCRUAL: A total of 10-27 patients will be accrued for this study within 10-27 months.
Interventions
DRUGgemcitabine hydrochloride
DRUGpaclitaxel
Sponsors
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Study design
Primary purpose
TREATMENT
Eligibility
Sex/Gender
ALL
Age
18 Years to 120 Years
Healthy volunteers
No
Inclusion criteria
DISEASE CHARACTERISTICS: * Histologically confirmed progressive regional or metastatic transitional cell carcinoma of the urothelium * Mixed histologies containing a component of transitional cell carcinoma allowed * Bidimensionally measurable disease * No clinical evidence of CNS metastases * Clinically unsuspected organ-confined prostate cancer found at time of cystoprostatectomy allowed PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 Life expectancy: * Not specified Hematopoietic: * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin no greater than 1.5 mg/dL * SGOT no greater than 2.5 times upper limit of normal (ULN) and alkaline phosphatase normal OR * Alkaline phosphatase no greater than 4 times ULN and SGOT normal OR * SGOT less than 1.5 times ULN and alkaline phosphatase less than 2.5 times ULN Renal: * Creatinine no greater than 3.0 mg/dL * Glomerular filtration rate no greater than 50 mL/min Cardiovascular: * No history of American Heart Association class III or IV heart disease * No uncontrolled congestive heart failure * No severe cardiac arrhythmias Other: * Not pregnant or nursing * Fertile patients must use effective contraception * No preexisting peripheral neuropathy grade 2 or greater * No active unresolved infection requiring parenteral antibiotics within the past 7 days * No other malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix PRIOR CONCURRENT THERAPY: Biologic therapy: * No prior systemic biologic response modifier therapy for advanced disease * Prior intravesical BCG for superficial disease allowed Chemotherapy: * Prior intravesical chemotherapy for superficial disease allowed * No prior chemotherapy for advanced disease * At least 6 months since prior adjuvant/neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) or cisplatin, methotrexate, and vinblastine (CMV), or cisplatin as a radiosensitizer Endocrine therapy: * Not specified Radiotherapy: * At least 4 weeks since prior radiotherapy * No concurrent radiotherapy Surgery: * See Disease Characteristics * At least 4 weeks since prior major surgery and recovered Other: * No concurrent hemodialysis
Countries
United States
Outcome results
None listed